https://www.selleckchem.com/products/hrs-4642.html
Bardet-Biedl syndrome (BBS) is primarily a multisystem nonmotile ciliopathy. In this study, we describe the successful establishment and characterization of an iPSC line from a patient diagnosed with BBS who was compound heterozygous for the BBS7 variants c.849 + 1G C (splicing) and c.754G A (p.D252N). To assess how patient characteristics and study design influence the effectiveness of control interventions in hand OA trials. The study protocol was registered in PROSPERO (CRD42020163473). Two authors independently searched f
Like
Comment
Share
